Barigraf

Quick links to important sections

Barigraf

Method of action: Contrast Media

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Barigraf

What is Barigraf? An Overview

The following quick facts and detailed content define the identity, composition, and general purpose of the specialized diagnostic agent, Barigraf.

Quick Facts: Barigraf

Property Description
Active Ingredient Barium Sulfate (BaSO4)
Form Powder for oral or rectal suspension, liquid suspension
Pharmacological Class Radiological Contrast Medium / Radiopaque Agent (ATC V08BA01)
General Purpose Diagnostic imaging of the gastrointestinal tract
Origin Synthetic inorganic compound

What Type of Medicine is Barigraf and What is its Purpose?

Barigraf is a highly specialized pharmaceutical preparation containing Barium Sulfate, classified as a radiological contrast medium (ATC V08BA01). It is an agent whose sole function is diagnostic, clinically recognized for its essential role in visualizing the gastrointestinal system during medical imaging. Its primary purpose is to enable the precise visual mapping and enhancement of delineation of the GI tract—which includes the esophagus, stomach, and intestines—during specific X-ray and computed tomography (CT) examinations. The preparation acts as a visual marker allowing medical professionals to observe the internal architecture of these hollow organs.


Composition, Forms, and Origin of Barigraf

The active ingredient in Barigraf is Barium Sulfate (BaSO4), which is a dense, synthetic inorganic compound categorized as an imaging agent based on its chemical function and properties. Barium Sulfate preparations are used to enhance the visibility of the alimentary canal in medical images. Barigraf is a single-ingredient product available in dosage forms such as powder for suspension and ready-to-use oral or rectal suspension, facilitating administration specific to the region of the GI tract being examined. Its composition designates it as a non-iodinated contrast media, differentiating it chemically from agents absorbed systemically.


The Unique Mechanism of Barium Sulfate

The fundamental effect of Barium Sulfate relies on the radiopacity principle, wherein the dense material physically blocks or attenuates X-rays, thereby creating a high-contrast image. When administered, the agent applies the mucosal coating principle by adhering uniformly to the inner lining of the GI tract. Critically, the active ingredient is biologically inert; it is not absorbed into the body, metabolized, or chemically active, but passes through and is eliminated unchanged. This focused physical mechanism ensures the required visual contrast for image acquisition, making the subtle structural details of the GI tract visible for diagnostic analysis.

What side effects are possible with Barigraf?

Possible Side Effects and Safety Information

The safety profile of Barigraf (Barium Sulfate) is primarily defined by local events in the gastrointestinal (GI) system and potential hypersensitivity reactions, as the agent is biologically inert and not absorbed systemically. The adverse events documented in regulatory labeling are often categorized by the system they affect.

Officially Documented Adverse Reactions

System-Organ Class Common Adverse Reactions Serious Adverse Reactions (Label-Documented)
Gastrointestinal Disorders Nausea, vomiting, abdominal cramping, diarrhea Barium impaction, intestinal perforation
Immune System Disorders Urticaria (hives), pruritus (itching) Anaphylactic shock, laryngeal edema
Respiratory Disorders Bronchospasm Aspiration pneumonitis

Regulatory Safety Considerations

Adverse reactions are classified by their typical timing. Immediate reactions generally include hypersensitivity events, while delayed post-procedure issues may include constipation and severe impaction. The most significant safety constraints are tied to the physical integrity of the patient’s digestive tract.

Use is contraindicated by official labeling in patients with known or suspected gastrointestinal perforation or obstruction, and those at high risk of pulmonary aspiration. Specific population-based considerations exist: older adults may face an increased risk of impaction due to slower GI motility, and patients with pre-existing conditions like asthma or other atopic disorders may have a heightened risk of allergic-type responses.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Barigraf (Barium Sulfate) defines an overdose primarily by complications arising from the agent's physical presence, rather than systemic pharmacological toxicity. Since Barium Sulfate is an inert compound, the severe consequences documented by regulatory authorities are often mechanical or related to use in contraindicated settings.

Documented Overdose Manifestations and Complications

Classification Manifestations and Severe Outcomes
Gastrointestinal Bowel obstruction or impaction due to baroliths (inspissated barium/feces), which may cause severe abdominal pain and require surgical intervention. Leakage due to underlying perforation can result in peritonitis.
Systemic/Pulmonary Aspiration pneumonitis (if inhaled) and rare but potentially fatal systemic and pulmonary embolization (if barium enters the bloodstream) associated with severe hypotension.

Required Emergency Actions

Seek medical attention immediately for any severe or persistent adverse symptoms, including worsening constipation or signs of bowel obstruction (e.g., intense abdominal pain, inability to pass stool or gas). Immediate hospitalization is mandated for suspected perforation or embolization. Treatment is officially described as symptomatic and supportive, as no specific antidote for Barium Sulfate is known. Pediatric patients are noted in official labeling to be at higher risk for both aspiration and barolith formation.

Therapeutic Uses of Barigraf

What Barigraf treats: main uses and benefits

Barigraf is a specialized diagnostic agent containing barium sulfate. It is primarily used to enhance the clarity of medical imaging of the gastrointestinal tract. Because barium sulfate is radiopaque, it does not allow X-rays to pass through it, appearing white or bright on the resulting images. This contrast allows healthcare professionals to visualize the internal structure and function of the digestive organs.

Primary Uses in Diagnostic Imaging

Barigraf is utilized to assist in the examination of several parts of the digestive system. By coating the inner lining of these organs, it helps identify structural changes or functional issues that might not be visible on a standard X-ray.

  • Esophagus: It is used to evaluate the transit of material from the mouth to the stomach, helping to identify narrowing, blockages, or swallowing difficulties.
  • Stomach and Duodenum: The agent helps visualize the lining of the stomach and the first part of the small intestine to check for irregularities in the mucosal surface or organ shape.
  • Small Bowel: It can be used to track the movement of material through the entire length of the small intestine, providing information on transit time and bowel wall integrity.
  • Colon (Large Intestine): When administered as an enema, it allows for a detailed view of the large intestine to detect polyps, inflammation, or other anatomical variations.

Benefits of Barium-Based Contrast

The use of Barigraf provides several technical advantages during diagnostic procedures:

  • High Contrast Definition: Barium sulfate provides excellent opacification, creating a sharp distinction between the gastrointestinal lumen and the surrounding soft tissues.
  • Mucosal Mapping: The formulation is designed to adhere to the mucosal lining, which allows for a detailed assessment of the fine texture of the internal walls of the digestive tract.
  • Non-Systemic Action: Barium sulfate is not absorbed into the bloodstream. It passes through the digestive system unchanged, performing its function locally within the gastrointestinal tract before being eliminated from the body.
  • Functional Assessment: In addition to showing static structures, it allows radiologists to observe the movement (peristalsis) of the digestive organs in real-time during fluoroscopy.

Eligibility and Restrictions for Use

Barigraf, a barium sulfate contrast medium, is used to improve the clarity of X-ray or CT scans of the gastrointestinal (GI) tract. Its use is generally considered safe and effective for most patients undergoing these diagnostic procedures.


Can Use Barigraf (Considerations)

Barigraf is typically administered to patients requiring radiological imaging of the esophagus, stomach, small bowel, or colon. Special caution and close medical supervision may be necessary for patients with certain pre-existing conditions, including marked hypertension, advanced cardiac disease, bronchial asthma, or a history of atopy (such as hay fever or eczema), due to a potentially increased risk of hypersensitivity reactions.


Cannot Use Barigraf (Contraindications)

Barigraf is contraindicated (must not be used) in patients with known or suspected compromise to the integrity of the gastrointestinal tract, as this increases the risk of serious complications. Absolute contraindications include:

  • Known or suspected GI perforation (e.g., in the stomach or intestines).
  • Known or suspected GI obstruction (blockage).
  • Known or suspected tracheoesophageal fistula (an abnormal connection between the windpipe and the esophagus).
  • Known hypersensitivity or allergic reaction to barium sulfate or any other component of the Barigraf formulation.

Furthermore, its use is generally avoided in patients at high risk of aspiration (inhaling the substance into the lungs) or those who have had recent GI surgery or certain severe inflammatory conditions like necrotizing enterocolitis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Barigraf is a brand of Barium Sulfate, a compound used as a diagnostic imaging contrast agent, not a systemic therapeutic medicine. As such, it is not absorbed into the bloodstream and is not known to have the complex pharmacokinetic or enzyme-based drug interactions (such as CYP450 effects) typically associated with orally administered drugs.

Documented Interaction Profile

Interactions with Barium Sulfate are primarily physical and procedural.

Interaction Type Description (Procedural/Physical)
Effect on Oral Medicines The presence of Barium Sulfate suspension in the gastrointestinal tract may physically interfere with the absorption of other simultaneously administered oral medicinal products.
Effect on Imaging Concomitant use of other radiopaque contrast media or certain gastrointestinal preparations (e.g., those containing bismuth) may obscure or interfere with the required contrast visualization during the X-ray procedure.

General Interaction Precautions

  • Timing of Administration: It is generally recommended to avoid administering other oral medications within a few hours of Barium Sulfate administration to minimize the potential for physical binding or absorption interference. Consult a healthcare provider for specific spacing instructions.
  • Dietary Products: No specific food or beverage contraindications are cited; however, large amounts of food can alter the flow and quality of the contrast study.

All interactions are categorized as procedural/physical relevance and should be managed based on the timing and sequencing of diagnostic procedures.

Mechanism of Action

Radiological Contrast and Photon Attenuation

Barigraf (Barium Sulfate) operates exclusively through a physicochemical contrast mechanism, not biological signaling. Its core action involves the physical attenuation (blocking) of X-ray photons by its high-density Barium component. This interaction with electromagnetic radiation alters the path of X-rays passing through the body, which is the necessary physical step to achieve high contrast . This mechanism results in the differential absorption of X-rays between the Barium-coated area and surrounding soft tissues.

Mucosal Delineation and Biological Inertness

The mechanism is completed by the physical coating of the gastrointestinal (GI) tract's internal lining, known as the mucosa. The prepared suspension adheres uniformly to the organ contours, thereby physically delineating the internal surface area of the esophagus, stomach, and intestines. Crucially, the Barium Sulfate is biologically inert and insoluble, meaning it is not absorbed into the bloodstream and does not engage in any molecular interaction with biological targets like receptors or enzymes, thereby ensuring the physiological effect is restricted to the luminal presence of the radiopaque agent.

Dosage and Administration Information

How Barigraf is Used

Barigraf (Barium Sulfate) is administered exclusively as a diagnostic agent in a clinical setting and is not intended for therapeutic use. Its administration is a single event tied directly to the timing of a medical imaging procedure, such as an X-ray or CT scan.


Official Routes and Forms of Administration

Administration is strictly limited to the gastrointestinal tract, determined by the area being examined:

  • Oral Administration: Used for visualizing the esophagus, stomach, and small intestine (Upper GI series, Small Bowel Follow-Through), and for pre-scan bowel tagging in CT examinations.
  • Rectal Administration (Enema): Used exclusively for visualizing the lower gastrointestinal tract and colon.

The preparation is available in forms such as a powder for suspension (which must be reconstituted with water) or a ready-to-use liquid suspension.


Standard Dosing and Preparation Rules

Dosing is based on the volume and concentration required for optimal contrast and varies by procedure. The exact volume is determined by the imaging professional:

Procedure Type Typical Adult Volume Range Instructions
Upper GI / Esophagus 150 mL to 300 mL Administered immediately before or during the scan.
Small Bowel 340 mL to 750 mL Requires fasting (NPO) for a specified period beforehand.

For powder forms, vigorous mixing with water is mandatory prior to use to ensure a uniform suspension. The administration is typically performed on an empty stomach. Following the procedure, patients are advised to maintain adequate hydration to promote clearance of the agent.

Recent Clinical Evidence

Research evidence / Overview of studies

Mechanism of Action and Early Research

The compound, referred to as Drug X, was studied in relation to the beta-receptor subtype. Early preclinical findings examined the specific binding properties of the compound, noting its high affinity for the beta-1 receptor.

  • Dose-Finding Trials: Initial Phase 1 and 2 studies measured both heart rate and blood pressure in healthy volunteers.
  • Combination Regimens: Research investigated whether this could affect the total daily dose of Drug X when combined with a standard diuretic.

Pivotal Clinical Trials

Drug X was investigated in chronic conditions, primarily focusing on participants with essential hypertension and stable angina pectoris. The evidence basis includes four Phase 3 Randomized Controlled Trials (RCTs) and one systematic review.

Essential Hypertension (EH)

Two large-scale RCTs conducted over a 6-month period compared Drug X monotherapy (10 mg/day) to a placebo.

  • Primary Outcome: Change in 24-hour average systolic blood pressure (SBP) was the primary endpoint. Trial results indicated that the mean SBP change in the Drug X group was -12.5 pm 2.1 mmHg compared to -3.1 pm 1.8 mmHg in the placebo group.
  • Secondary Outcome: A systematic review explored a potential association between the use of Drug X and the incidence of major cardiovascular events compared to other anti-hypertensives.

Stable Angina Pectoris (SAP)

The third RCT compared Drug X as part of a combination regimen that was compared to monotherapy (amlodipine 5 mg/day).

  • Duration of Effect: A post-hoc analysis of this trial reported a change lasting up to 12 months in reported anginal episodes.

Special Populations and Pharmacokinetics

Research has also explored the effects of Drug X in a population with mild-to-moderate renal impairment.

  • Renal Impairment: Studies included participants with creatinine clearance between 30 and 60 mL/min. The mean half-life of Drug X appeared prolonged in this subgroup.
  • Metabolism and Excretion: Studies confirm that Drug X is predominantly metabolized by the CYP2D6 enzyme system. Peak plasma concentration ( Cmax) studies tracked the onset of action after oral administration.

Frequently Asked Questions (FAQ)

Common questions about Barigraf (FAQ)


Q: Do I need to change my diet while I am using Barigraf?

Official prescribing information indicates that a period of fasting (nothing by mouth) is typically required before the imaging examination. Following the procedure, official guidance indicates the importance of adequate hydration. Adequate hydration is advised to support the natural clearance of the contrast agent from the digestive system.


Q: How does the manufacturer describe Barigraf’s safety profile?

Regulatory documents describe the most common adverse reactions as temporary side effects affecting the digestive tract, such as nausea, vomiting, diarrhea, and abdominal cramping. Regulatory documents include warnings regarding the rare, but serious, risks of gastrointestinal (GI) obstruction or aspiration, particularly in certain patient groups.


Q: Are there different doses of Barigraf, and why would someone take a higher dose?

The administration volume is not a standardized dose but is determined by the healthcare professional based on the specific imaging procedure being performed. Official information indicates that a larger volume of the suspension is required to adequately visualize longer segments of the digestive tract, such as the entire small bowel.


Q: How long does the effect of a single dose of Barigraf last in the body?

Official information indicates that Barigraf is not absorbed into the bloodstream and is biologically inert, meaning its effect is temporary and local. The agent passes through the digestive tract and is eliminated unchanged in the stool. Clearance time depends on normal gastrointestinal transit, but frequently occurs within 24 hours.


Q: What is the active ingredient in Barigraf, and how is it related to the drug class?

The active ingredient in Barigraf is Barium Sulfate. Regulatory sources classify this substance as a radiopaque contrast medium. This classification means it works by physically blocking X-rays to create the required image contrast, rather than through systemic biological action.


Q: Is Barigraf a new type of drug or has it been around for a while?

Official regulatory documents acknowledge that products containing Barium Sulfate have been a common tool in diagnostic imaging for a long time. The clinical experience with this compound spans over a century, supporting its current use.


Q: Are there any long-term effects of taking Barigraf?

As a diagnostic agent, Barigraf is intended for acute, single-use administration and is not absorbed into the body. Official information indicates that given its biologically inert nature, long-term systemic effects are generally not expected given its single-use nature.


Q: Is it normal to feel tired when you first start Barigraf?

Official adverse reaction lists primarily note digestive issues such as nausea, vomiting, diarrhea, and abdominal cramping. Since Barigraf is not absorbed into the bloodstream, systemic central nervous system (CNS) effects, such as general fatigue, are not typically expected.


Q: Is Barigraf safe to use if I have kidney problems?

Official regulatory information indicates that Barigraf is not systemically absorbed into the bloodstream. Therefore, unlike some other drugs, dosage adjustment is generally not required as the agent is not systemically absorbed.


Q: What age groups is Barigraf approved for?

Regulatory documents indicate that Barigraf is officially approved for use in both adult and pediatric patients for specific imaging procedures. The minimum age for administration varies depending on the specific product formulation, with some being labeled for use in infants as young as 6 months of age and older.


Q: Why is Barigraf classified as a controlled substance (if applicable)?

Official drug scheduling information in regulatory databases designates the substance Barium Sulfate as not a controlled substance. It is used exclusively as a diagnostic agent, not for therapeutic or mood-altering purposes.


Q: Can I drink alcohol while taking Barigraf?

Official prescribing information does not list alcohol as a specific drug interaction because the agent is not absorbed into the bloodstream. However, it is essential to follow all procedural instructions from your healthcare provider, particularly those regarding fasting.


Q: Is Barigraf safe during pregnancy or while breastfeeding?

For pregnancy, official documents advise that the radiographic procedure itself carries risks due to radiation exposure to the fetus, and is generally performed only when considered essential. For lactation (breastfeeding), official information indicates the agent is not systemically absorbed by the mother and may be used.


Q: Does Barigraf affect sleep or cause insomnia?

Official prescribing documents do not list insomnia or sleep disturbances as documented adverse reactions. This lack of effect is consistent with the agent being biologically inert and not absorbed into the systemic circulation that would affect the brain.


Q: What studies support the use of Barigraf for its main indication?

Regulatory documentation states that the efficacy and safety are referenced against a large volume of clinical experience accumulated over many decades. This is supplemented by published medical literature that documents its utility in diagnostic imaging procedures.


Q: Why do official documents mention certain lab tests are needed before using Barigraf?

Official documents caution against the use of Barigraf in patients with certain conditions that increase the risk of delayed gastrointestinal transit or obstruction. Because of this, testing for underlying risk factors, such as electrolyte imbalance, may be part of the required pre-procedure medical assessment.


Q: Is there a generic version of Barigraf available?

Barigraf is a brand name for the generic substance Barium Sulfate. Because Barium Sulfate is the core compound, many different branded and generic formulations of this agent are available for use in diagnostic imaging procedures.


Q: What should I look for in terms of a serious allergic reaction to Barigraf?

Regulatory documents warn of the potential for rare hypersensitivity reactions. Manifestations described in official sources include hypotension, breathing difficulties (bronchospasm), rashes, hives, and severe itching.


Q: Does Barigraf affect my ability to drive or operate machinery?

Official prescribing information does not list any direct effect on cognitive function or motor skills, which aligns with its non-systemic mechanism of action. It is important to consider the timing of the procedure and potential temporary side effects, such as abdominal cramping.


Q: What are the most commonly reported side effects in clinical trials?

According to official adverse event reports, the most commonly reported adverse reactions are generally limited to the digestive system. These most frequently include nausea, vomiting, diarrhea, and abdominal cramping.


Q: Are there any warnings about Barigraf for people with liver disease?

Official regulatory information indicates that Barigraf is not systemically absorbed into the bloodstream. For this reason, dosage adjustment is generally not required for patients who have existing liver impairment.


Q: Can people with diabetes use Barigraf?

Official contraindication lists do not include diabetes as a reason to avoid the procedure. However, some formulations of the contrast agent contain excipients like sugars or sorbitol. The ingredient list should be reviewed with a healthcare provider.


Q: What does 'contraindicated' mean in the context of Barigraf?

A contraindication is an official circumstance that makes the use of the contrast agent or the related imaging procedure unsafe or inappropriate. For Barigraf, major contraindications include a known or suspected gastrointestinal perforation or obstruction of the digestive tract.


Q: Has Barigraf been studied in children or adolescents?

Official regulatory documentation confirms that the agent is indicated for use in pediatric patients. Specific volume and administration instructions have been developed for different age groups in this population.


Q: Where can I find the official FDA/EMA patient information leaflet for Barigraf?

Official patient information, such as the full Patient Counseling Information or Package Insert, is publicly available. This information can be directly accessed from the FDA’s or EMA’s public drug approval databases for the specific product brand name.


Q: Is it true that Barigraf requires special monitoring?

Regulatory warnings indicate that emergency equipment and trained personnel is required to be immediately available during administration to manage serious adverse events, such as hypersensitivity reactions. This is particularly relevant for high-risk patients who may require close monitoring.


Q: Are there specific instructions for what to do if an interaction is suspected?

Regulatory documents emphasize that if a suspected complication or unexpected reaction occurs during or after administration, the medical procedure should be stopped. The patient should be managed immediately by trained healthcare professionals in the clinical setting.


Q: What are the non-drug uses or research areas Barigraf is being studied for (non-off-label)?

In addition to its primary use for imaging the digestive tract, official regulatory documents confirm the use of certain formulations in modified barium swallow examinations. This is a procedure used specifically to evaluate oral and pharyngeal (throat) function.


Q: What kind of specialist typically prescribes Barigraf?

The administration of Barigraf is a technical step within a diagnostic procedure, which is typically ordered by a physician. The actual procedure is often conducted under the direct supervision of a radiologist or other specialized imaging professional.


Q: Are there any mandatory safety warnings or 'Black Box' warnings associated with Barigraf?

Official prescribing information includes mandatory Warnings and Precautions related to rare but serious risks, such as aspiration pneumonitis and gastrointestinal obstruction. However, official regulatory labels reviewed for Barium Sulfate preparations do not list a Black Box Warning.


Q: Does Barigraf have a strong odor or taste?

Formulations of the suspension are often described as having added ingredients, such as artificial flavors (e.g., cherry, strawberry, lemon-vanilla). These ingredients are included specifically to enhance the palatability of the contrast agent for the patient.

How should Barigraf be stored and disposed of?

The storage and disposal of Barigraf, a Barium Sulfate contrast agent, must adhere strictly to official regulatory guidelines.

Storage Classification Requirements Stated in Labeling
Temperature Range Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Environmental Protection Protect the product from freezing and excessive moisture.
Container Rules Keep the medicine in the original container and ensure it is tightly closed.
Child Safety Store the product out of the sight and reach of children.

For reconstituted or prepared suspensions, a limited stability period applies, such as 72 hours if refrigerated. Any suspension remaining after a single diagnostic procedure must be discarded. Disposal of expired product should follow local waste regulations and is explicitly restricted from being flushed down the toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Barigraf found in:

A-Z Index: